ArticleVeterinary world2025
Establishment and characterization of canine mammary tumors 622: A novel luminal B CMT cell line exhibiting partial epithelial-mesenchymal transition and intermediate drug sensitivity.
Article in Veterinary world, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aim: Canine mammary tumors (CMTs) serve as valuable comparative models for human breast cancer (HBC) owing to their shared biological and molecular features. However, well-defined cell lines representing the luminal B subtype remain limited. This study aimed to establish and characterize a novel CMT cell line, designated CMT-622, to expand available Materials and Methods: Primary tumor tissue was collected from an 11-year-old female dog diagnosed with high-grade mammary carcinoma (T3N1M0). Tumor cells were isolated using enzymatic digestion and differential adhesion. Morphological, cytogenetic, and immunophenotypic characteristics were assessed using hematoxylin-eosin staining, immunohistochemistry, and immunofluorescence. Growth kinetics, clonogenicity, and chromosomal analyses were performed, and tumorigenicity was evaluated through xenograft assays in nude mice. Drug sensitivity and apoptosis were compared with two existing CMT lines (CMT-1211 and CMT-n7) using the cell counting kit-8 (CCK)-8 assay and flow cytometry. Results: CMT-622 cells maintained stable proliferation beyond 40 passages with a doubling time of 46.23 h and >15% cloning efficiency. Karyotyping revealed hyperdiploidy (80-110 chromosomes; modal = 87). Immunohistochemistry and immunofluorescence confirmed estrogen receptor (+), progesterone receptor (-), and human epidermal growth factor receptor 2 (weak +) expression, consistent with a luminal B phenotype. Co-expression of cytokeratin-18 and vimentin indicated a partial epithelial-mesenchymal transition (EMT) state. In nude mice, CMT-622 exhibited moderate tumorigenicity and pulmonary metastasis. The line showed intermediate osthole sensitivity (half-maximal inhibitory concentration = 50.48 μM) and an apoptosis rate of 21%, between CMT-1211 and CMT-n7, indicating balanced proliferative and drug-responsive behavior. Conclusion: CMT-622 represents a newly established luminal B CMT cell line with stable growth, EMT plasticity, and moderate drug sensitivity, reflecting clinically relevant tumor aggressiveness. Its molecular and phenotypic consistency across
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.